Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District)

Aim. To analyze major epidemiological parameters of multiple myeloma, i.e. registered incidence, prevalence, mortality, and survival in Novosibirsk, megalopolis in Siberian Federal District. Materials & Methods. The study covered medical records of 335 patients with newly diagnosed multiple myeloma (MM) treated from January 1, 2006 to December 31, 2016 at the Center of Hematology in Novosibirsk. Median age was 67 years (range 30–89), the trial enrolled 218 (65 %) women and 117 (35 %) men. Results. Over the last decade the mean registered MM incidence in Novosibirsk increased by 1.6 times, and MM prevalence increased by 4.9 times. These parameters correspond to 2.4 and 13.8 per 100,000 population per year, respectively, with the linear trend of growth which demonstrates not only the increased number of patients with newly diagnosed MM, but the increased longevity of them. MM incidence and prevalence parameters are significantly higher in women than in men, which most probably can be accounted for by specific administrative factors in the Novosibirsk region. Yearly mortality of MM patients decreased from 28.3 % to 8.2 % with a negative linear trend over the entire analyzed period, which is most likely to be associated with availability of new drugs and transplantation procedures. Conclusion. The obtained epidemiological data will enable to plan the provision of timely and effective care for MM patients and to elaborate a system of judicious allocation of costly equipment and drugs

Clinical Recommendations for the Diagnosis and Treatment of Chronic Myeloid Leukemia

This article is the 4th edition of the recommendations for the diagnosis and treatment of chronic myeloid leukemia. The group of authors reviewed and discussed relevant new publications, and included the significant remarks and comments of experts. Particular attention was paid to the control of risk factors for the development of arterial vascular events and their prevention, and adverse effects of the long-term therapy with tyrosine kinase inhibitors, which were being increasingly reported in recent years